<code id='C4B7DAA13C'></code><style id='C4B7DAA13C'></style>
    • <acronym id='C4B7DAA13C'></acronym>
      <center id='C4B7DAA13C'><center id='C4B7DAA13C'><tfoot id='C4B7DAA13C'></tfoot></center><abbr id='C4B7DAA13C'><dir id='C4B7DAA13C'><tfoot id='C4B7DAA13C'></tfoot><noframes id='C4B7DAA13C'>

    • <optgroup id='C4B7DAA13C'><strike id='C4B7DAA13C'><sup id='C4B7DAA13C'></sup></strike><code id='C4B7DAA13C'></code></optgroup>
        1. <b id='C4B7DAA13C'><label id='C4B7DAA13C'><select id='C4B7DAA13C'><dt id='C4B7DAA13C'><span id='C4B7DAA13C'></span></dt></select></label></b><u id='C4B7DAA13C'></u>
          <i id='C4B7DAA13C'><strike id='C4B7DAA13C'><tt id='C4B7DAA13C'><pre id='C4B7DAA13C'></pre></tt></strike></i>

          Home / hotspot / knowledge

          knowledge


          knowledge

          author:fashion    Page View:55

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In